Orient EuroPharma Co., Ltd. (TPEX: 4120)
48.50
-0.40 (-0.82%)
Sep 11, 2024, 11:16 AM CST
Orient EuroPharma Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Revenue | 4,499 | 4,592 | 4,730 | 4,767 | 5,384 | 6,093 | Upgrade
|
Revenue Growth (YoY) | -3.63% | -2.93% | -0.77% | -11.45% | -11.65% | 10.58% | Upgrade
|
Cost of Revenue | 2,288 | 2,445 | 2,698 | 2,616 | 2,962 | 3,279 | Upgrade
|
Gross Profit | 2,211 | 2,147 | 2,032 | 2,151 | 2,422 | 2,815 | Upgrade
|
Selling, General & Admin | 1,793 | 1,868 | 1,922 | 1,918 | 1,938 | 751.86 | Upgrade
|
Research & Development | 247.95 | 206.6 | 259.84 | 331.09 | 366.56 | 394.6 | Upgrade
|
Operating Expenses | 2,055 | 2,077 | 2,182 | 2,246 | 2,305 | 2,478 | Upgrade
|
Operating Income | 155.88 | 70.61 | -149.54 | -95.68 | 117.36 | 336.41 | Upgrade
|
Interest Expense | -105.59 | -106.1 | -69.53 | -38.04 | -30.23 | -24.92 | Upgrade
|
Interest & Investment Income | 58.66 | 50.86 | 20.96 | 11.85 | 16.04 | 20.22 | Upgrade
|
Earnings From Equity Investments | -24.47 | -18.27 | -30.14 | -19.14 | -16.88 | -8.13 | Upgrade
|
Currency Exchange Gain (Loss) | -39.17 | -25.59 | -177.51 | 11.6 | 125.63 | 12.96 | Upgrade
|
Other Non Operating Income (Expenses) | 64.71 | 50.08 | 40.54 | 41.69 | 36.45 | 26.95 | Upgrade
|
EBT Excluding Unusual Items | 110.01 | 21.6 | -365.23 | -87.71 | 248.36 | 363.5 | Upgrade
|
Gain (Loss) on Sale of Assets | 229.51 | 234.5 | 72.35 | 182.38 | 1.07 | 1.49 | Upgrade
|
Asset Writedown | - | - | -35.3 | -10 | - | - | Upgrade
|
Other Unusual Items | 1.53 | 0.16 | 0.05 | 0.1 | 0.46 | 0.02 | Upgrade
|
Pretax Income | 341.05 | 256.25 | -328.14 | 84.77 | 249.88 | 365.01 | Upgrade
|
Income Tax Expense | 134.35 | 86.97 | -32.77 | 10.47 | 143.01 | 228.23 | Upgrade
|
Earnings From Continuing Operations | 206.7 | 169.29 | -295.37 | 74.3 | 106.88 | 136.78 | Upgrade
|
Minority Interest in Earnings | -61.93 | -25.34 | -15.44 | 45.88 | 92.43 | 110.89 | Upgrade
|
Net Income | 144.76 | 143.94 | -310.8 | 120.17 | 199.3 | 247.66 | Upgrade
|
Net Income to Common | 144.76 | 143.94 | -310.8 | 120.17 | 199.3 | 247.66 | Upgrade
|
Net Income Growth | - | - | - | -39.70% | -19.53% | 0.38% | Upgrade
|
Shares Outstanding (Basic) | 87 | 87 | 87 | 87 | 87 | 87 | Upgrade
|
Shares Outstanding (Diluted) | 87 | 87 | 87 | 87 | 87 | 87 | Upgrade
|
Shares Change (YoY) | 0.23% | 0.23% | -0.24% | -0.21% | 0.07% | -0.03% | Upgrade
|
EPS (Basic) | 1.67 | 1.66 | -3.58 | 1.39 | 2.30 | 2.86 | Upgrade
|
EPS (Diluted) | 1.67 | 1.66 | -3.58 | 1.38 | 2.29 | 2.84 | Upgrade
|
EPS Growth | - | - | - | -39.74% | -19.37% | 0.35% | Upgrade
|
Free Cash Flow | -210.82 | 21.58 | -857.91 | -1,485 | 375.77 | 102.39 | Upgrade
|
Free Cash Flow Per Share | -2.42 | 0.25 | -9.89 | -17.08 | 4.31 | 1.18 | Upgrade
|
Dividend Per Share | 1.000 | 1.000 | - | 0.850 | 1.500 | 1.800 | Upgrade
|
Dividend Growth | - | - | - | -43.33% | -16.67% | 0% | Upgrade
|
Gross Margin | 49.15% | 46.76% | 42.96% | 45.12% | 44.99% | 46.19% | Upgrade
|
Operating Margin | 3.47% | 1.54% | -3.16% | -2.01% | 2.18% | 5.52% | Upgrade
|
Profit Margin | 3.22% | 3.13% | -6.57% | 2.52% | 3.70% | 4.06% | Upgrade
|
Free Cash Flow Margin | -4.69% | 0.47% | -18.14% | -31.15% | 6.98% | 1.68% | Upgrade
|
EBITDA | 321.43 | 235.75 | 7.04 | 60.33 | 278.32 | 484.04 | Upgrade
|
EBITDA Margin | 7.15% | 5.13% | 0.15% | 1.27% | 5.17% | 7.94% | Upgrade
|
D&A For EBITDA | 165.55 | 165.14 | 156.57 | 156.01 | 160.97 | 147.63 | Upgrade
|
EBIT | 155.88 | 70.61 | -149.54 | -95.68 | 117.36 | 336.41 | Upgrade
|
EBIT Margin | 3.46% | 1.54% | -3.16% | -2.01% | 2.18% | 5.52% | Upgrade
|
Effective Tax Rate | 39.39% | 33.94% | - | 12.35% | 57.23% | 62.53% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.